Lecanemab has given us more years together. That’s not ‘minute’ nor ‘minimal’ to me,” writes one reader in STAT’s letters to ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

Alzheimer’s disease — which affects an estimated 7 million Americans — is notoriously difficult to detect, especially in its ...

The factor that tips you over the edge from being at risk for a disease to actually developing the disease is not always clear. Now, researchers from Japan report one factor that triggers problematic ...

More than 2 years since the original trial data for lecanemab in Alzheimer's disease was published,1 and over 1·5 years since approval by the US Food and Drug Administration, brain volume data have ...

“This is a wonderful piece of work,” said Henrik Zetterberg at the University of Gothenburg, Sweden. He was not involved in ...

A new biomarker test can detect early-stage tau protein clumping up to a decade before it appears on brain scans, improving ...

Researchers from Osaka University find that peristaltic pump action and high shear flow forces promote amyloid nucleation.

Alzheimer's patients with a baseline CDR-SB score of 3.5 could expect approximately 4 additional months (95% CI 2-7 months) ...

Researchers from Osaka University found that peristaltic pump flow mechanically breaks supersaturation to induce amyloid ...

At the Human Amyloid Imaging (HAI) meeting, held January 15-17, researchers focused on new techniques—all based on tau and ...